Results of a Prospective Phase 2 Pilot Trial of 177Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression-Reference-Cited by-同舟云学术

Results of a Prospective Phase 2 Pilot Trial of 177Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression

Published:2019-02 Issue:1 Volume:17 Page:15-22
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Emmett Louise,Crumbaker Megan,Ho Bao,Willowson Kathy,Eu Peter,Ratnayake Lalith^ORCID,Epstein Richard,Blanksby Ashley,Horvath Lisa,Guminski Alex,Mahon Kate,Gedye Craig,Yin Charlotte,Stricker Phillip,Joshua Anthony M.

Funder

Paul Ramsay Foundation

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference17 articles.

1. [177Lu]–PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study;Hofman;Lancet Oncol,2018

2. Lutetium-177–labelled anti–prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis;Calopedos;Prostate Cancer Prostatic Dis,2017

3. Radioligand therapy with 177Lu–PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer;Rahbar;Clin Nucl Med,2016

4. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617;Kratochwil;J Nucl Med,2016

5. Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy;Emmett;J Med Radiat Sci,2017

Cited by 136 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Significance of Baseline Clinical and [68Ga]Ga-PSMA PET Derived Parameters on Biochemical Response, Overall Survival, and PSA Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Undergoing [177Lu]Lu-PSMA Therapy;Nuklearmedizin - NuclearMedicine;2024-09-03

2. Analysis of Molecular Imaging and Laboratory Baseline Biomarkers in PSMA-RLT: Whole-Body Total Lesion PSMA (TLP) Predicts Overall Survival;Cancers;2024-07-26

3. Hematological and renal toxicity in mice after three cycles of high activity [177Lu]Lu-PSMA-617 with or without human α1-microglobulin;Scientific Reports;2024-05-11

4. Pathway to Approval of Innovative Radiopharmaceuticals in China;Journal of Nuclear Medicine;2024-05

5. Development of a Visually Calculated SUV_mean(HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to¹⁷⁷Lu-PSMA Therapy: Comparison with Quantitative SUV_meanand Patient Outcomes;Journal of Nuclear Medicine;2024-04-18